GSK Clinical Trial Registry Sees Shift In Use Of Website
This article was originally published in The Pink Sheet Daily
Executive Summary
Number of hits per day to the trial website is increasing, but the percentage of visitors who spend at least 10 minutes on the site is dropping, the company says. "I'm a little disappointed at the usage rate and the way it fell off," GSK VP Metz says at DIA annual meeting.
You may also be interested in...
GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005
The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.